Skip to main content
Vigonvita Life Sciences Co., Ltd. logo

Vigonvita Life Sciences Co., Ltd. — Investor Relations & Filings

Ticker · 2630 ISIN · CNE1000076N3 HKEX Manufacturing
Open in API
Filings indexed 44 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2630

About Vigonvita Life Sciences Co., Ltd.

http://www.vigonvita.cn

Vigonvita Life Sciences Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule drugs. The company operates an integrated R&D platform targeting high-need therapeutic areas, specifically neurological and neuropsychiatric disorders, reproductive health, and viral infections. Its comprehensive pipeline includes the oral nucleoside antiviral candidate MINDVY® (VV116), which has been clinically studied for COVID-19 and RSV, and ONVITA® (TPN171). Vigonvita emphasizes high-quality development, evidenced by its participation in significant national programs, including the National Key R&D Program and the Major New Drug Innovation Technology Major Project, often involving international clinical research collaborations.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT ON THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2025
Regulatory Filings Classification · 80% confidence The document is a short supplemental announcement on the Annual Report already published (under 5,000 characters), providing auditor confirmation with no substantive financial statements or data. It does not itself constitute an annual report or interim report, nor is it announcing dividends, board changes, or capital actions. It serves as a regulatory announcement under Hong Kong Exchange rules and thus falls into the general Regulatory Filings category rather than being the report itself or another specific filing type.
2026-05-25 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for the month ended 30 April 2026. It details movements in authorised/registered share capital, issued shares, treasury shares, and public float sufficiency confirmation. It includes confirmations pursuant to specific HKEX listing rules and is a regulatory compliance submission rather than a financial report or announcement of financial results. The document is not an annual or interim report, earnings release, or investor presentation. It is a regulatory filing providing detailed share capital and shareholding information as required by the exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-05-07 English
(1) PROPOSED ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS APPENDICES; (2) ELECTION OF THE NEW SESSION OF THE BOARD; AND (3) POSTPONEMENT OF THE ANNUAL G
Board/Management Information Classification · 95% confidence The document is an announcement from Vigonvita Life Sciences Co., Ltd. regarding corporate governance changes, specifically the proposed abolition of the Supervisory Committee, amendments to the Articles of Association, election of a new board session, and postponement of the Annual General Meeting (AGM). It includes detailed information about board candidates and governance structure changes. The document is not a full annual report or financial statement but rather a formal announcement related to board and management changes and AGM arrangements. It does not contain financial results or audit information but focuses on governance and management updates. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length and detail support a high confidence level.
2026-04-30 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT' and contains detailed sections typical of an annual report, including Corporate Information, Financial Highlights, Operation Highlights, Chairman's Statement, Management Discussion and Analysis, Directors and Senior Management, Corporate Governance Report, Environmental, Social and Governance Report, Independent Auditor's Report, and full consolidated financial statements. The content includes comprehensive financial data for the year ended December 31, 2025, operational achievements, corporate governance details, and auditor's report, all consistent with a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement or summary. Therefore, the document is classified as an Annual Report (10-K). FY 2025
2026-04-30 English
Articles of Association
Governance Information Classification · 90% confidence The document is titled “Articles of Association” and comprises the company’s constitutional governance charter, detailing share capital, shareholder meetings, board composition, management structure, audit provisions, and amendment procedures. It is a governance rulebook rather than an earnings announcement, proxy statement, or annual/quarterly financial report. This aligns precisely with the Governance Information category (Code: CGR).
2026-04-23 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON APRIL 23, 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is an announcement of the poll results of an Extraordinary General Meeting (EGM), detailing vote counts, percentages, and resolutions passed. It fits the category of official voting results announcements. Therefore, it should be classified under Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-23 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.